Concerning Medicare Open Enrollment: It is especially important for GIST patients to carefully consider available plans, as one of the financial support resources that has been available through Novartis Pharmaceuticals will end on January 1, 2021.
The LRG is pleased to welcome Shari Reid and Dr. Amy Kenworthy as country liaisons supporting GIST patients in Australia.
Fall is finally here, and with it comes the onset of flu season. The flu is a difficult illness for everyone, but for cancer patients, it can be devastating. It is especially challenging in this year that has already taxed everyone with the uncertainty of COVID-19.
This is the monthly update for the LRG Outreach & Engagement Department, detailing events for October and volunteer positions available.
Dealing daily with a pandemic along with GIST can be a daunting task and it may feel difficult sometimes to even face a new day. Paying attention to your mental health is an important part of everyday self-care. We have composed a Daily Checklist to help you consciously acknowledge where you are at the beginning of your day, work with those feelings, and reflect on your successes.
The LRG was fortunate to get a few minutes with GIST specialist, Jonathan Trent, MD, Sylvester Comprehensive Cancer Center, who shared his experience with his patients over the past few months during the coronavirus pandemic.
Hope is an important resource during difficulty times. Mary Garland, Director of Communications for the LRG, shares her observations on hope.
Cancer and COVID both leave us feeling so out of control. Grief expert Claire M. Schwartz shares her thoughts on the similarities of the trauma of cancer & pandemics and offers some advice on coping.
The LRG has been granted permission from the NCCN to share the most recent NCCN Guidelines for Patients® with soft tissue sarcoma, most specifically the section on GIST, which the LRG has endorsed.
Blueprint Medicines presented a poster titled “The Cost Impact of Increased Molecular Testing Rates for the Treatment of Patients with Gastrointestinal Stromal Tumors” at the annual meeting of the AMCP.
